Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers
© 2018 Elsevier B.V. West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2019
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/46011 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.46011 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.460112019-08-28T13:51:00Z Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers Tatsuhiko Ozawa Hideyuki Masaki Tomohiko Takasaki Ikuko Aoyama Takahiro Yumisashi Atsushi Yamanaka Eiji Konishi Yoh Ohnuki Atsushi Muraguchi Hiroyuki Kishi Osaka Prefectural Institute of Public Health Osaka University University of Toyama Mahidol University Kanagawa Prefectural Institute of Public Health Kindai University Immunology and Microbiology Pharmacology, Toxicology and Pharmaceutics © 2018 Elsevier B.V. West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4–14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses. 2019-08-23T11:20:30Z 2019-08-23T11:20:30Z 2018-06-01 Article Antiviral Research. Vol.154, (2018), 58-65 10.1016/j.antiviral.2018.04.011 18729096 01663542 2-s2.0-85045462667 https://repository.li.mahidol.ac.th/handle/123456789/46011 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85045462667&origin=inward |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Immunology and Microbiology Pharmacology, Toxicology and Pharmaceutics |
spellingShingle |
Immunology and Microbiology Pharmacology, Toxicology and Pharmaceutics Tatsuhiko Ozawa Hideyuki Masaki Tomohiko Takasaki Ikuko Aoyama Takahiro Yumisashi Atsushi Yamanaka Eiji Konishi Yoh Ohnuki Atsushi Muraguchi Hiroyuki Kishi Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
description |
© 2018 Elsevier B.V. West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4–14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses. |
author2 |
Osaka Prefectural Institute of Public Health |
author_facet |
Osaka Prefectural Institute of Public Health Tatsuhiko Ozawa Hideyuki Masaki Tomohiko Takasaki Ikuko Aoyama Takahiro Yumisashi Atsushi Yamanaka Eiji Konishi Yoh Ohnuki Atsushi Muraguchi Hiroyuki Kishi |
format |
Article |
author |
Tatsuhiko Ozawa Hideyuki Masaki Tomohiko Takasaki Ikuko Aoyama Takahiro Yumisashi Atsushi Yamanaka Eiji Konishi Yoh Ohnuki Atsushi Muraguchi Hiroyuki Kishi |
author_sort |
Tatsuhiko Ozawa |
title |
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
title_short |
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
title_full |
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
title_fullStr |
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
title_full_unstemmed |
Human monoclonal antibodies against West Nile virus from Japanese encephalitis-vaccinated volunteers |
title_sort |
human monoclonal antibodies against west nile virus from japanese encephalitis-vaccinated volunteers |
publishDate |
2019 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/46011 |
_version_ |
1763490925728759808 |